The latest myeloma news

FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for multiple myeloma
On July 30, 2024, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj in combination with…